Research
Cellular
Drug-related adverse events (AEs) were reported by 39.0% of participants in parts 1 + 2 and 30.6% in part 3.
Practitioners should be aware of the incidence of AEs when considering BI 1820237 for treatment.
StrongSupportsmedium confidence
Drug-related AEs, mainly gastrointestinal events, were reported by 39.0% of participants (n = 23) in parts 1 + 2 and 30.6% of participants (n = 11) in part 3.
Why this rating
Based on the randomized phase I study design.
Source
A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
Nadine Beetz et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15984
rct · n=74Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →